Mary Weiser-Evans
Concepts (425)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocytes, Smooth Muscle | 21 | 2023 | 261 | 4.060 |
Why?
| | PTEN Phosphohydrolase | 14 | 2025 | 162 | 3.980 |
Why?
| | Muscle, Smooth, Vascular | 25 | 2023 | 445 | 3.680 |
Why?
| | Vascular Remodeling | 8 | 2022 | 189 | 2.660 |
Why?
| | Atherosclerosis | 4 | 2023 | 415 | 2.170 |
Why?
| | Plaque, Atherosclerotic | 2 | 2023 | 57 | 1.600 |
Why?
| | Adventitia | 2 | 2022 | 40 | 1.280 |
Why?
| | Kruppel-Like Transcription Factors | 2 | 2020 | 66 | 1.180 |
Why?
| | Myofibroblasts | 3 | 2025 | 126 | 1.110 |
Why?
| | Stem Cells | 6 | 2023 | 593 | 1.080 |
Why?
| | Fibrosis | 12 | 2023 | 552 | 1.050 |
Why?
| | Lung Neoplasms | 19 | 2023 | 2494 | 0.990 |
Why?
| | Vascular System Injuries | 3 | 2023 | 71 | 0.970 |
Why?
| | Mice | 43 | 2024 | 17774 | 0.890 |
Why?
| | Cell Proliferation | 18 | 2021 | 2479 | 0.870 |
Why?
| | Neointima | 4 | 2022 | 15 | 0.830 |
Why?
| | Hypercholesterolemia | 1 | 2023 | 105 | 0.780 |
Why?
| | Tunica Intima | 5 | 2010 | 84 | 0.780 |
Why?
| | Spinocerebellar Ataxias | 1 | 2022 | 6 | 0.780 |
Why?
| | Galectin 3 | 1 | 2022 | 21 | 0.770 |
Why?
| | Animals | 63 | 2024 | 36862 | 0.760 |
Why?
| | Cell Differentiation | 10 | 2023 | 1987 | 0.710 |
Why?
| | Heart-Assist Devices | 4 | 2022 | 552 | 0.710 |
Why?
| | DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2020 | 17 | 0.680 |
Why?
| | Serum Response Factor | 3 | 2016 | 33 | 0.650 |
Why?
| | Carotid Artery Injuries | 5 | 2010 | 41 | 0.640 |
Why?
| | Chemokine CXCL12 | 2 | 2011 | 81 | 0.630 |
Why?
| | Coronary Restenosis | 1 | 2019 | 21 | 0.630 |
Why?
| | Coronary Vessels | 2 | 2018 | 246 | 0.630 |
Why?
| | Mice, Knockout | 16 | 2024 | 3009 | 0.620 |
Why?
| | Cyclin D1 | 1 | 2019 | 68 | 0.620 |
Why?
| | Mice, Inbred C57BL | 22 | 2024 | 5753 | 0.600 |
Why?
| | High-Throughput Screening Assays | 1 | 2020 | 160 | 0.590 |
Why?
| | Arteries | 4 | 2022 | 269 | 0.550 |
Why?
| | Cells, Cultured | 19 | 2025 | 4197 | 0.550 |
Why?
| | Vascular Diseases | 1 | 2019 | 244 | 0.530 |
Why?
| | Tumor Microenvironment | 8 | 2021 | 674 | 0.520 |
Why?
| | Rats | 20 | 2019 | 5639 | 0.510 |
Why?
| | Heparan Sulfate Proteoglycans | 4 | 2003 | 26 | 0.510 |
Why?
| | Mice, Transgenic | 9 | 2020 | 2164 | 0.490 |
Why?
| | PPAR gamma | 7 | 2019 | 182 | 0.480 |
Why?
| | Gene Expression Regulation | 6 | 2024 | 2608 | 0.480 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 7 | 2023 | 1078 | 0.460 |
Why?
| | Cell Division | 8 | 2004 | 796 | 0.440 |
Why?
| | Disease Models, Animal | 17 | 2024 | 4284 | 0.430 |
Why?
| | Hypertension, Pulmonary | 5 | 2023 | 1904 | 0.430 |
Why?
| | Acute Kidney Injury | 5 | 2023 | 811 | 0.420 |
Why?
| | Signal Transduction | 18 | 2019 | 5078 | 0.410 |
Why?
| | Hypertension | 1 | 2022 | 1285 | 0.410 |
Why?
| | Hyperplasia | 5 | 2020 | 175 | 0.410 |
Why?
| | MicroRNAs | 2 | 2017 | 699 | 0.400 |
Why?
| | Protein Kinases | 4 | 2014 | 319 | 0.390 |
Why?
| | Transforming Growth Factor beta1 | 3 | 2023 | 165 | 0.360 |
Why?
| | Bone Marrow Cells | 2 | 2011 | 316 | 0.360 |
Why?
| | Ureteral Obstruction | 3 | 2021 | 64 | 0.340 |
Why?
| | Cell Movement | 5 | 2012 | 969 | 0.340 |
Why?
| | Kidney | 6 | 2021 | 1467 | 0.330 |
Why?
| | Muscle, Smooth | 2 | 2023 | 155 | 0.330 |
Why?
| | Macrophages | 4 | 2021 | 1544 | 0.320 |
Why?
| | Autocrine Communication | 2 | 2014 | 41 | 0.310 |
Why?
| | Cell Dedifferentiation | 3 | 2016 | 32 | 0.310 |
Why?
| | Phospholipases A2, Cytosolic | 1 | 2009 | 7 | 0.310 |
Why?
| | Angiotensin II | 3 | 2021 | 99 | 0.310 |
Why?
| | Group IV Phospholipases A2 | 3 | 2017 | 47 | 0.300 |
Why?
| | Platelet-Derived Growth Factor | 4 | 2020 | 91 | 0.290 |
Why?
| | Cisplatin | 3 | 2020 | 319 | 0.290 |
Why?
| | Carcinoma, Lewis Lung | 2 | 2019 | 15 | 0.280 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 2 | 2004 | 35 | 0.270 |
Why?
| | Focal Adhesion Protein-Tyrosine Kinases | 4 | 2019 | 34 | 0.270 |
Why?
| | Male | 26 | 2024 | 67560 | 0.270 |
Why?
| | Proteins | 2 | 2006 | 1012 | 0.270 |
Why?
| | Proto-Oncogene Proteins c-akt | 7 | 2014 | 436 | 0.270 |
Why?
| | Heart Failure | 4 | 2023 | 2234 | 0.260 |
Why?
| | Actins | 3 | 2018 | 416 | 0.260 |
Why?
| | Hypoxia | 2 | 2013 | 1111 | 0.260 |
Why?
| | Rats, Sprague-Dawley | 9 | 2016 | 2486 | 0.260 |
Why?
| | Nuclear Proteins | 2 | 2023 | 712 | 0.260 |
Why?
| | TOR Serine-Threonine Kinases | 5 | 2014 | 412 | 0.250 |
Why?
| | Proto-Oncogene Proteins | 3 | 2004 | 647 | 0.250 |
Why?
| | Acetyltransferases | 1 | 2006 | 22 | 0.250 |
Why?
| | Endothelial Cells | 2 | 2022 | 779 | 0.240 |
Why?
| | Protein-Tyrosine Kinases | 3 | 2003 | 434 | 0.240 |
Why?
| | Adenocarcinoma | 5 | 2017 | 939 | 0.240 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 2 | 2019 | 260 | 0.240 |
Why?
| | Inflammation | 4 | 2023 | 2836 | 0.240 |
Why?
| | RNA Interference | 5 | 2014 | 467 | 0.230 |
Why?
| | Embryonic Development | 1 | 2006 | 118 | 0.230 |
Why?
| | Fibromuscular Dysplasia | 1 | 2024 | 7 | 0.230 |
Why?
| | Myeloid Cells | 2 | 2019 | 148 | 0.230 |
Why?
| | Phosphatidylinositol 3-Kinases | 4 | 2010 | 365 | 0.230 |
Why?
| | Aortic Valve | 2 | 2025 | 352 | 0.220 |
Why?
| | Gene Expression | 3 | 2014 | 1501 | 0.220 |
Why?
| | Humans | 34 | 2025 | 137294 | 0.220 |
Why?
| | Ribosomal Protein S6 | 1 | 2004 | 15 | 0.220 |
Why?
| | Phenotype | 10 | 2024 | 3202 | 0.220 |
Why?
| | Corn Oil | 1 | 2023 | 5 | 0.210 |
Why?
| | Inflammation Mediators | 2 | 2021 | 514 | 0.210 |
Why?
| | Receptors, LDL | 1 | 2023 | 47 | 0.210 |
Why?
| | Azotemia | 1 | 2023 | 7 | 0.210 |
Why?
| | Proprotein Convertase 9 | 1 | 2023 | 73 | 0.210 |
Why?
| | Phosphorylation | 6 | 2019 | 1759 | 0.200 |
Why?
| | Lipoxygenase Inhibitors | 2 | 2021 | 37 | 0.200 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2004 | 172 | 0.200 |
Why?
| | Rejuvenation | 1 | 2022 | 18 | 0.190 |
Why?
| | Disease Progression | 7 | 2019 | 2752 | 0.190 |
Why?
| | Fibroblasts | 2 | 2024 | 993 | 0.190 |
Why?
| | Aortic Valve Stenosis | 1 | 2025 | 229 | 0.190 |
Why?
| | Gene Regulatory Networks | 1 | 2024 | 309 | 0.190 |
Why?
| | Extracellular Matrix | 4 | 2021 | 527 | 0.190 |
Why?
| | Arachidonate 12-Lipoxygenase | 1 | 2021 | 18 | 0.190 |
Why?
| | Aortic Valve Insufficiency | 1 | 2022 | 47 | 0.190 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2020 | 251 | 0.190 |
Why?
| | Polycystic Kidney Diseases | 2 | 2019 | 76 | 0.190 |
Why?
| | Arachidonate 15-Lipoxygenase | 1 | 2021 | 23 | 0.190 |
Why?
| | Nephritis | 1 | 2021 | 22 | 0.190 |
Why?
| | DNA Helicases | 1 | 2023 | 145 | 0.180 |
Why?
| | Assisted Circulation | 1 | 2021 | 26 | 0.180 |
Why?
| | Cytokines | 4 | 2021 | 2090 | 0.180 |
Why?
| | Dual-Specificity Phosphatases | 1 | 2021 | 11 | 0.180 |
Why?
| | Adaptive Immunity | 2 | 2023 | 165 | 0.180 |
Why?
| | Cholesterol | 1 | 2023 | 410 | 0.180 |
Why?
| | Zebrafish | 1 | 2006 | 495 | 0.180 |
Why?
| | Metformin | 2 | 2023 | 330 | 0.180 |
Why?
| | Cell Line, Tumor | 9 | 2019 | 3414 | 0.180 |
Why?
| | Transcription Factors | 4 | 2023 | 1720 | 0.180 |
Why?
| | Promoter Regions, Genetic | 5 | 2020 | 1250 | 0.180 |
Why?
| | Protein Kinase Inhibitors | 3 | 2023 | 916 | 0.170 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2021 | 145 | 0.170 |
Why?
| | Female | 17 | 2024 | 73052 | 0.170 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2023 | 236 | 0.170 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2017 | 1095 | 0.170 |
Why?
| | Blotting, Western | 3 | 2019 | 1226 | 0.170 |
Why?
| | Aortic Diseases | 1 | 2021 | 117 | 0.170 |
Why?
| | Jugular Veins | 1 | 2020 | 42 | 0.170 |
Why?
| | Homeostasis | 2 | 2022 | 619 | 0.170 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2019 | 189 | 0.160 |
Why?
| | Intestines | 1 | 2023 | 359 | 0.160 |
Why?
| | Arachidonate 5-Lipoxygenase | 2 | 2019 | 43 | 0.160 |
Why?
| | Wound Healing | 1 | 2022 | 329 | 0.160 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2020 | 134 | 0.160 |
Why?
| | Myocytes, Cardiac | 2 | 2014 | 528 | 0.160 |
Why?
| | GATA4 Transcription Factor | 1 | 2019 | 18 | 0.160 |
Why?
| | Kidney Tubules | 2 | 2019 | 117 | 0.160 |
Why?
| | Crohn Disease | 1 | 2023 | 244 | 0.160 |
Why?
| | Neovascularization, Physiologic | 1 | 2000 | 178 | 0.160 |
Why?
| | Azacitidine | 1 | 2020 | 141 | 0.150 |
Why?
| | Chromatin | 1 | 2023 | 519 | 0.150 |
Why?
| | Pulmonary Artery | 3 | 2021 | 1084 | 0.150 |
Why?
| | Catheterization | 4 | 2004 | 179 | 0.150 |
Why?
| | Wnt Signaling Pathway | 1 | 2020 | 192 | 0.150 |
Why?
| | Bone Marrow | 2 | 2017 | 286 | 0.150 |
Why?
| | AMP-Activated Protein Kinases | 2 | 2023 | 197 | 0.150 |
Why?
| | Metabolome | 1 | 2021 | 350 | 0.150 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2020 | 368 | 0.150 |
Why?
| | Mice, Knockout, ApoE | 1 | 2018 | 11 | 0.150 |
Why?
| | Flow Cytometry | 2 | 2019 | 1184 | 0.150 |
Why?
| | Epigenesis, Genetic | 1 | 2023 | 659 | 0.140 |
Why?
| | Sirolimus | 2 | 2014 | 275 | 0.140 |
Why?
| | Heart Ventricles | 2 | 2021 | 792 | 0.140 |
Why?
| | Skin | 1 | 2022 | 751 | 0.140 |
Why?
| | Interleukin-33 | 1 | 2017 | 50 | 0.140 |
Why?
| | Trans-Activators | 1 | 2020 | 398 | 0.140 |
Why?
| | Receptors, Complement | 1 | 2017 | 122 | 0.140 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2019 | 209 | 0.140 |
Why?
| | Epithelial Cells | 3 | 2019 | 1095 | 0.130 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2019 | 429 | 0.130 |
Why?
| | Immunotherapy | 2 | 2018 | 641 | 0.120 |
Why?
| | Ventricular Remodeling | 2 | 2023 | 262 | 0.120 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2021 | 916 | 0.120 |
Why?
| | Gene Deletion | 2 | 2014 | 392 | 0.120 |
Why?
| | Cell Cycle Proteins | 1 | 2019 | 613 | 0.120 |
Why?
| | Interferon-gamma | 1 | 2019 | 790 | 0.120 |
Why?
| | Energy Metabolism | 1 | 2021 | 920 | 0.120 |
Why?
| | Dinoprostone | 3 | 2016 | 191 | 0.120 |
Why?
| | B7-H1 Antigen | 1 | 2017 | 218 | 0.120 |
Why?
| | Focal Adhesion Kinase 1 | 3 | 2003 | 32 | 0.120 |
Why?
| | Autophagy | 2 | 2014 | 281 | 0.120 |
Why?
| | NF-kappa B | 2 | 2010 | 691 | 0.110 |
Why?
| | Intracellular Signaling Peptides and Proteins | 3 | 2019 | 455 | 0.110 |
Why?
| | Aorta | 3 | 2004 | 417 | 0.110 |
Why?
| | Retinoid X Receptors | 1 | 2014 | 39 | 0.110 |
Why?
| | Pleural Neoplasms | 1 | 2014 | 25 | 0.110 |
Why?
| | Interleukin-6 | 3 | 2023 | 778 | 0.110 |
Why?
| | Complement Activation | 1 | 2017 | 411 | 0.110 |
Why?
| | Culture Media, Serum-Free | 2 | 2004 | 48 | 0.110 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2014 | 53 | 0.110 |
Why?
| | Gene Amplification | 1 | 2014 | 105 | 0.110 |
Why?
| | Mesothelioma | 1 | 2014 | 43 | 0.110 |
Why?
| | Leukotrienes | 1 | 2013 | 37 | 0.110 |
Why?
| | Kidney Diseases | 1 | 2017 | 406 | 0.110 |
Why?
| | Paracrine Communication | 1 | 2014 | 65 | 0.100 |
Why?
| | Oligonucleotides, Antisense | 2 | 2004 | 111 | 0.100 |
Why?
| | Eicosanoids | 1 | 2013 | 62 | 0.100 |
Why?
| | Monocytes | 1 | 2016 | 563 | 0.100 |
Why?
| | Myocardial Contraction | 1 | 2014 | 340 | 0.100 |
Why?
| | RNA | 1 | 2019 | 924 | 0.100 |
Why?
| | Iloprost | 2 | 2010 | 45 | 0.100 |
Why?
| | Macrophages, Alveolar | 1 | 2016 | 392 | 0.100 |
Why?
| | Macrophage Activation | 1 | 2014 | 201 | 0.100 |
Why?
| | Up-Regulation | 2 | 2008 | 844 | 0.100 |
Why?
| | Cardiomyopathy, Hypertrophic | 1 | 2014 | 142 | 0.100 |
Why?
| | MAP Kinase Signaling System | 3 | 2021 | 321 | 0.100 |
Why?
| | Tumor Burden | 3 | 2020 | 309 | 0.100 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2019 | 612 | 0.100 |
Why?
| | Immunohistochemistry | 4 | 2021 | 1734 | 0.090 |
Why?
| | Heparitin Sulfate | 2 | 2003 | 50 | 0.090 |
Why?
| | Lipocalin-2 | 2 | 2023 | 79 | 0.090 |
Why?
| | Endothelium, Vascular | 1 | 2018 | 927 | 0.090 |
Why?
| | Splenectomy | 1 | 2011 | 62 | 0.090 |
Why?
| | Transforming Growth Factor beta | 1 | 2014 | 480 | 0.090 |
Why?
| | Protein Processing, Post-Translational | 2 | 2004 | 467 | 0.090 |
Why?
| | Cyclooxygenase 2 | 2 | 2010 | 178 | 0.090 |
Why?
| | T-Lymphocytes | 2 | 2017 | 1998 | 0.090 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2012 | 210 | 0.080 |
Why?
| | Histone Deacetylases | 1 | 2012 | 215 | 0.080 |
Why?
| | Green Fluorescent Proteins | 1 | 2011 | 390 | 0.080 |
Why?
| | Frizzled Receptors | 1 | 2010 | 25 | 0.080 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 3 | 2015 | 283 | 0.080 |
Why?
| | Case-Control Studies | 3 | 2024 | 3546 | 0.080 |
Why?
| | RNA, Small Interfering | 2 | 2010 | 622 | 0.080 |
Why?
| | Receptors, Epoprostenol | 1 | 2008 | 6 | 0.080 |
Why?
| | TRPP Cation Channels | 2 | 2019 | 84 | 0.070 |
Why?
| | Reperfusion Injury | 1 | 2011 | 279 | 0.070 |
Why?
| | Lung Injury | 1 | 2011 | 218 | 0.070 |
Why?
| | Glycoproteins | 1 | 2010 | 344 | 0.070 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2010 | 220 | 0.070 |
Why?
| | Adenosine Triphosphate | 2 | 2014 | 487 | 0.070 |
Why?
| | Severity of Illness Index | 2 | 2013 | 2836 | 0.070 |
Why?
| | Antineoplastic Agents | 2 | 2017 | 2135 | 0.070 |
Why?
| | Epoprostenol | 1 | 2008 | 136 | 0.070 |
Why?
| | Receptors, CXCR4 | 1 | 2008 | 86 | 0.070 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2010 | 327 | 0.070 |
Why?
| | Hematopoietic Stem Cells | 1 | 2011 | 402 | 0.070 |
Why?
| | Culture Media, Conditioned | 2 | 2014 | 110 | 0.070 |
Why?
| | Gene Silencing | 2 | 2019 | 195 | 0.070 |
Why?
| | Biomarkers | 4 | 2023 | 4164 | 0.060 |
Why?
| | Neoplasm Metastasis | 1 | 2009 | 658 | 0.060 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2008 | 278 | 0.060 |
Why?
| | Antihypertensive Agents | 1 | 2010 | 488 | 0.060 |
Why?
| | Middle Aged | 4 | 2024 | 33310 | 0.060 |
Why?
| | RNA, Messenger | 5 | 2010 | 2839 | 0.060 |
Why?
| | Mitogens | 1 | 2005 | 61 | 0.060 |
Why?
| | Neoplasm Transplantation | 2 | 2016 | 257 | 0.060 |
Why?
| | Apoptosis | 3 | 2020 | 2554 | 0.060 |
Why?
| | Acetylation | 1 | 2006 | 248 | 0.060 |
Why?
| | Animals, Genetically Modified | 1 | 2006 | 240 | 0.060 |
Why?
| | Protein Subunits | 1 | 2006 | 239 | 0.060 |
Why?
| | Mutation | 3 | 2023 | 3956 | 0.060 |
Why?
| | Pregnancy | 2 | 2016 | 6743 | 0.060 |
Why?
| | Gene Knockout Techniques | 2 | 2015 | 117 | 0.060 |
Why?
| | Enzyme Inhibitors | 2 | 2007 | 839 | 0.060 |
Why?
| | Cell Size | 2 | 2005 | 91 | 0.050 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 2 | 2015 | 171 | 0.050 |
Why?
| | Chromones | 1 | 2004 | 44 | 0.050 |
Why?
| | Basement Membrane | 1 | 2003 | 35 | 0.050 |
Why?
| | Gene Expression Profiling | 3 | 2016 | 1774 | 0.050 |
Why?
| | Androstadienes | 1 | 2004 | 107 | 0.050 |
Why?
| | Acute-Phase Reaction | 1 | 2023 | 41 | 0.050 |
Why?
| | Embryo, Mammalian | 2 | 2003 | 232 | 0.050 |
Why?
| | Furosemide | 1 | 2023 | 37 | 0.050 |
Why?
| | Tenascin | 1 | 2003 | 14 | 0.050 |
Why?
| | Glycosaminoglycans | 1 | 2003 | 84 | 0.050 |
Why?
| | Peroxidases | 1 | 2003 | 34 | 0.050 |
Why?
| | Morpholines | 1 | 2004 | 121 | 0.050 |
Why?
| | Peroxidase | 2 | 2015 | 176 | 0.050 |
Why?
| | Fibronectins | 1 | 2003 | 133 | 0.050 |
Why?
| | Transfection | 3 | 2014 | 947 | 0.050 |
Why?
| | Murinae | 1 | 2022 | 6 | 0.050 |
Why?
| | Ileum | 1 | 2023 | 119 | 0.050 |
Why?
| | Metalloproteases | 1 | 2022 | 43 | 0.050 |
Why?
| | Aniline Compounds | 1 | 2023 | 102 | 0.050 |
Why?
| | Coculture Techniques | 2 | 2014 | 239 | 0.050 |
Why?
| | Adult | 3 | 2024 | 37724 | 0.050 |
Why?
| | Matrix Metalloproteinases, Secreted | 1 | 2021 | 12 | 0.050 |
Why?
| | Long Term Adverse Effects | 1 | 2021 | 12 | 0.050 |
Why?
| | ADAMTS4 Protein | 1 | 2021 | 16 | 0.050 |
Why?
| | DNA Replication | 1 | 2003 | 238 | 0.050 |
Why?
| | Cadherins | 2 | 2016 | 205 | 0.050 |
Why?
| | Cell Line | 2 | 2018 | 2841 | 0.050 |
Why?
| | Aged | 2 | 2018 | 23851 | 0.050 |
Why?
| | Aorta, Thoracic | 1 | 2003 | 267 | 0.040 |
Why?
| | Cellular Microenvironment | 1 | 2021 | 84 | 0.040 |
Why?
| | Ventricular Function, Right | 1 | 2023 | 283 | 0.040 |
Why?
| | Recombinant Fusion Proteins | 1 | 2003 | 664 | 0.040 |
Why?
| | Neoplasms | 1 | 2015 | 2661 | 0.040 |
Why?
| | Vasoconstrictor Agents | 1 | 2021 | 139 | 0.040 |
Why?
| | Major Histocompatibility Complex | 1 | 2021 | 227 | 0.040 |
Why?
| | Blood Urea Nitrogen | 1 | 2020 | 54 | 0.040 |
Why?
| | Butadienes | 1 | 2020 | 36 | 0.040 |
Why?
| | Contractile Proteins | 1 | 2000 | 15 | 0.040 |
Why?
| | Leukocytes | 1 | 2021 | 312 | 0.040 |
Why?
| | Cell Fusion | 1 | 2000 | 52 | 0.040 |
Why?
| | Thiazolidinediones | 2 | 2011 | 137 | 0.040 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 2000 | 53 | 0.040 |
Why?
| | NADH, NADPH Oxidoreductases | 1 | 2019 | 18 | 0.040 |
Why?
| | Liver | 2 | 2023 | 1941 | 0.040 |
Why?
| | Growth Substances | 1 | 2000 | 147 | 0.040 |
Why?
| | Enzyme Activation | 2 | 2014 | 813 | 0.040 |
Why?
| | Genes, Tumor Suppressor | 1 | 2000 | 86 | 0.040 |
Why?
| | Suppressor of Cytokine Signaling 1 Protein | 1 | 2019 | 12 | 0.040 |
Why?
| | Cloning, Molecular | 1 | 2000 | 536 | 0.040 |
Why?
| | Glomerular Filtration Rate | 1 | 2023 | 745 | 0.040 |
Why?
| | ErbB Receptors | 1 | 2023 | 613 | 0.040 |
Why?
| | Chemokine CXCL9 | 1 | 2019 | 27 | 0.040 |
Why?
| | Mesoderm | 1 | 2020 | 144 | 0.040 |
Why?
| | Pyrimidinones | 1 | 2020 | 113 | 0.040 |
Why?
| | Tropoelastin | 1 | 1999 | 11 | 0.040 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 2003 | 404 | 0.040 |
Why?
| | Receptors, Leukotriene | 1 | 2019 | 14 | 0.040 |
Why?
| | Nitriles | 1 | 2020 | 172 | 0.040 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2019 | 59 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 452 | 0.040 |
Why?
| | Luciferases | 2 | 2010 | 150 | 0.040 |
Why?
| | Pyridones | 1 | 2020 | 168 | 0.040 |
Why?
| | Proteoglycans | 1 | 1999 | 107 | 0.040 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2003 | 858 | 0.040 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 267 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 976 | 0.040 |
Why?
| | Antibodies, Blocking | 1 | 2017 | 33 | 0.030 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2023 | 802 | 0.030 |
Why?
| | Complement C3d | 1 | 2017 | 67 | 0.030 |
Why?
| | Tumor Cells, Cultured | 2 | 2010 | 954 | 0.030 |
Why?
| | Neoplasm Proteins | 1 | 2020 | 434 | 0.030 |
Why?
| | Complement C3 | 1 | 2017 | 209 | 0.030 |
Why?
| | Myocardial Ischemia | 1 | 2018 | 263 | 0.030 |
Why?
| | Arachidonic Acid | 1 | 2016 | 120 | 0.030 |
Why?
| | Immunoglobulin M | 1 | 2017 | 288 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2019 | 413 | 0.030 |
Why?
| | Immunocompetence | 1 | 2016 | 42 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2024 | 2419 | 0.030 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2017 | 215 | 0.030 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2015 | 162 | 0.030 |
Why?
| | Lymphocyte Depletion | 1 | 2015 | 135 | 0.030 |
Why?
| | Organ Culture Techniques | 2 | 2007 | 156 | 0.030 |
Why?
| | Kidney Function Tests | 1 | 2015 | 159 | 0.030 |
Why?
| | Homozygote | 1 | 2015 | 203 | 0.030 |
Why?
| | Time Factors | 2 | 2017 | 6818 | 0.030 |
Why?
| | Chemokines | 1 | 2016 | 228 | 0.030 |
Why?
| | Caspase 3 | 1 | 2015 | 246 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2015 | 346 | 0.030 |
Why?
| | Ventricular Function, Left | 1 | 2018 | 540 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2017 | 870 | 0.030 |
Why?
| | Tetrahydronaphthalenes | 1 | 2014 | 29 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-sis | 2 | 2005 | 37 | 0.030 |
Why?
| | Intracellular Space | 1 | 2014 | 68 | 0.030 |
Why?
| | Macrophage Colony-Stimulating Factor | 1 | 2014 | 21 | 0.030 |
Why?
| | Heart | 1 | 2018 | 657 | 0.030 |
Why?
| | Chemokine CCL2 | 1 | 2014 | 115 | 0.030 |
Why?
| | Carcinogenesis | 1 | 2016 | 217 | 0.030 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2014 | 87 | 0.030 |
Why?
| | Pyridazines | 1 | 2014 | 56 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2015 | 508 | 0.030 |
Why?
| | Ventricular Myosins | 1 | 2014 | 35 | 0.030 |
Why?
| | Superoxides | 1 | 2014 | 202 | 0.030 |
Why?
| | Clone Cells | 1 | 2014 | 266 | 0.030 |
Why?
| | Microfilament Proteins | 1 | 2014 | 131 | 0.030 |
Why?
| | Cardiomegaly | 1 | 2014 | 175 | 0.030 |
Why?
| | Calcium-Binding Proteins | 1 | 2014 | 218 | 0.030 |
Why?
| | Integrases | 1 | 2014 | 121 | 0.030 |
Why?
| | Imidazoles | 1 | 2014 | 239 | 0.030 |
Why?
| | Femoral Artery | 1 | 2014 | 179 | 0.020 |
Why?
| | Metabolic Networks and Pathways | 1 | 2013 | 182 | 0.020 |
Why?
| | Mice, Nude | 1 | 2014 | 696 | 0.020 |
Why?
| | Lipid Metabolism | 1 | 2016 | 512 | 0.020 |
Why?
| | Muscle, Skeletal | 1 | 2022 | 1709 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2019 | 1274 | 0.020 |
Why?
| | Cardiac Surgical Procedures | 1 | 2017 | 530 | 0.020 |
Why?
| | Hypoglycemic Agents | 2 | 2011 | 1283 | 0.020 |
Why?
| | Capillary Leak Syndrome | 1 | 2011 | 12 | 0.020 |
Why?
| | Chemokine CXCL1 | 1 | 2011 | 76 | 0.020 |
Why?
| | Vasoconstriction | 1 | 2012 | 202 | 0.020 |
Why?
| | Benzamides | 1 | 2012 | 217 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2011 | 388 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 2011 | 185 | 0.020 |
Why?
| | Cell Lineage | 1 | 2012 | 348 | 0.020 |
Why?
| | Snail Family Transcription Factors | 1 | 2010 | 17 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2017 | 1431 | 0.020 |
Why?
| | Regional Blood Flow | 1 | 2012 | 474 | 0.020 |
Why?
| | Models, Animal | 1 | 2011 | 384 | 0.020 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2010 | 82 | 0.020 |
Why?
| | Matrix Metalloproteinases | 1 | 2010 | 94 | 0.020 |
Why?
| | Interleukin-10 | 1 | 2011 | 302 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2011 | 372 | 0.020 |
Why?
| | Spleen | 1 | 2011 | 514 | 0.020 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2008 | 68 | 0.020 |
Why?
| | Myocardium | 1 | 2014 | 1002 | 0.020 |
Why?
| | Cell Adhesion | 1 | 2010 | 467 | 0.020 |
Why?
| | Pyrimidines | 1 | 2012 | 471 | 0.020 |
Why?
| | Metabolomics | 1 | 2013 | 679 | 0.020 |
Why?
| | Pyridines | 1 | 2012 | 506 | 0.020 |
Why?
| | Sulindac | 1 | 2007 | 16 | 0.020 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2007 | 50 | 0.020 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2008 | 184 | 0.020 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2008 | 158 | 0.020 |
Why?
| | Culture Media | 1 | 2007 | 167 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2007 | 298 | 0.020 |
Why?
| | Prognosis | 1 | 2016 | 4026 | 0.020 |
Why?
| | Transgenes | 1 | 2007 | 180 | 0.020 |
Why?
| | Neoplasms, Experimental | 1 | 2007 | 176 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2011 | 1242 | 0.020 |
Why?
| | Genes, jun | 1 | 2005 | 10 | 0.020 |
Why?
| | Respiratory Mucosa | 1 | 2008 | 323 | 0.020 |
Why?
| | CCAAT-Enhancer-Binding Protein-delta | 1 | 2005 | 6 | 0.020 |
Why?
| | CCAAT-Enhancer-Binding Proteins | 1 | 2005 | 37 | 0.020 |
Why?
| | Heterotrimeric GTP-Binding Proteins | 1 | 2005 | 13 | 0.010 |
Why?
| | GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2005 | 20 | 0.010 |
Why?
| | Blood Pressure | 1 | 2012 | 1776 | 0.010 |
Why?
| | Genetic Markers | 1 | 2005 | 344 | 0.010 |
Why?
| | Heparin Lyase | 1 | 2003 | 5 | 0.010 |
Why?
| | Genotype | 1 | 2008 | 1923 | 0.010 |
Why?
| | Transcriptional Activation | 1 | 2005 | 378 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2007 | 2052 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2005 | 767 | 0.010 |
Why?
| | Cattle | 1 | 2004 | 981 | 0.010 |
Why?
| | Protein Structure, Tertiary | 1 | 2003 | 867 | 0.010 |
Why?
| | Binding Sites | 1 | 2003 | 1309 | 0.010 |
Why?
| | Homeodomain Proteins | 1 | 2003 | 506 | 0.010 |
Why?
| | Bromodeoxyuridine | 1 | 1999 | 80 | 0.010 |
Why?
| | In Situ Hybridization | 1 | 1999 | 316 | 0.010 |
Why?
| | Tissue Distribution | 1 | 1999 | 330 | 0.010 |
Why?
| | Muscle Development | 1 | 1999 | 111 | 0.010 |
Why?
| | Models, Biological | 1 | 2003 | 1773 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2003 | 1501 | 0.010 |
Why?
| | Gestational Age | 1 | 1999 | 902 | 0.010 |
Why?
| | DNA | 1 | 1999 | 1459 | 0.010 |
Why?
|
|
Weiser-Evans's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|